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1521-6934/© 2016 Elsevier Ltd. All rights reservedWe conducted a prospective randomized single blind e subject
study in the University Clinic of Gynecology of Pius-Hospital Old-
enburg. The primary objective of the ADBEE study was to assess
the safety and manageability of ADBLOCK when used as an adjunct
to laparoscopic surgery for the primary of myomas in women
wishing to improve pregnancy outcomes.
The study population included 32 women aged between 18e45
years, in good general health condition, who have not completed
their family planning and who are undergoing primary (‘virgin’)
laparoscopic myomectomy with an aim to improve pregnancy
outcomes. The patients were randomized in 2 groups, ADBLOCK
arm with 21 patients and surgery only arm with 11 patients. The46 Norderstedt, Germany.
ar).
.
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ded to treatment group assignment until completion of uterine
suturing and prior to removal of the endoscope. A vigorous follow-
up of subjects was organized, focusing on its two critical charac-
teristics: completeness and duration. Completeness represented
the percentage of subjects who returned to every planed follow e
up appointments. The patients were evaluated in a speciﬁc period
of time, which deﬁned the duration of follow-up. Safety of the
ADBLOCK was estimated after analyzing and documentation of any
adverse events occurred, clinical and physical examination of pa-
tients as well as evaluation of laboratory measures.
There were 25 adverse events reported in ADBLOCK treatment
group and 12 events in NO-ADBLOCK group over the 24-months
treatment. All adverse events in both treatment arms were not
anticipated, with all events in the ADBLOCK group being resolved.
At 28 days, there was no signiﬁcant difference in proportion of
events between the two treatments (p ¼ 0.440). Overall, the
number of events reported was low and the severity of events was
generally mild with an unlikely or no relationship to treatment.
There were no unanticipated device related adverse events seen in
both treatment groups over the immediate post-operative period
or during the 24 months follow up period.
By 12 weeks all patients reported their wound as healing well or
healed and at 6 months all wounds were reported as healed. There
were no differences between both treatment groups regarding the
use of painkillers over 24 months follow up period.
This clinical ﬁrst e in e human study, sustained by a rigorous
follow-up of the subjects has demonstrated that ADBLOCK is a safe
product, presenting no additional safety risk or burden to the
patients over surgery alone. The device was relatively easy to use,
with a low device failure rate that had no impact on the surgical
procedures.
© 2016 Elsevier Ltd. All rights reserved.Introduction
Adhesions are the most frequent complication of abdominopelvic surgery [1,2]. They are an almost
inevitable consequence of abdominopelvic surgery, the healthcare burden being considerable [3,4].
Despite advances in surgery including laparoscopy, the burden has not changed and the risk of
admission to hospital for adhesion e related complications following gynaecological procedures is
similar whether they are undertaken by laparotomy or laparoscopy [4].
The postoperative adhesions have a substantial impact on healthcare resources due to many related
complications such as intestinal obstruction, infertility, chronic pelvic pain and also due to consider-
able increase of economic costs [5e11].
The amplitude and the gravity of adhesions have been underestimated by most of the surgeons
since the occurrence of adhesions is unpredictable [12,13]. Recurrent complications are often treated
by physicians or specialists other than the initial surgeon and many years after the initial operation.
Even if the adhesions can be present they may be asymptomatic, in which case they remain undi-
agnosed in most of the cases [2,12]. Moreover, the efforts to prevent adhesions remain unsuccessful,
because of the biochemical complexities and still incompletely understood aetiology of the adhesions
formation and due to the lack of good predictive animal models [14]. Also, there has been a long track
record of failure or limited use of traditional prevention strategies, until the recent introduction of
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surgical technique and applying adjuvants [14e16]. A careful surgical technique that all surgeons
should apply includes a gentle tissue handling, minimizing the surgical trauma, rigorous haemostasis,
cautious cauterization to prevent ischaemia, irrigation to minimize serosal drying, avoiding intra-
peritoneal infection and also avoiding the introduction of foreign material such as glove powder [17].
While optimal surgical technique following the principles of microsurgery in open and laparoscopic
procedures is a fundamental step in reducing adhesions [12,18], surgery alone is not enough to
prevent adhesions formation [19]. The use of safe and effective anti-adhesion agents as part of the
strategy to reduce the formation of adhesions has become mandatory [20]. Following the efforts of
different authoritative organizations and groups of expert surgeons, there is a strong recommenda-
tion for research of new, safe and effective anti-adhesion agents which can be used in laparoscopic
and open surgery to reduce de novo adhesions formation, as well as those that reform following
adhesiolysis [2,12,18,21e24].
Material and methods
We conducted a ﬁrste ine human clinical trial based on randomized, controlledmulticentric study
in order to assess the safety, manageability and usability of the ADBLOCK system. The ADBLOCK is a
site-speciﬁc sprayable barrier gel, based on a dextrin polymer, used as an adhesion e reduction agent
[1]. Given the fact that removal of myomas associates a high risk of adhesions development [25], the
ADBLOCK was used as an adjunct to laparoscopic surgery for the primary removal of myomas in
women wishing to improve pregnancy outcomes. The trial was conducted in compliance with Good
Clinical Practice (GCP) and the Declaration of Helsinki [1]. The Study Protocol, respected the conditions
of approval imposed by the IRB/EC from Hannover, Germany.
ADBLOCK System is a site-speciﬁc sprayable that was investigated for potential European CE device
approval as an adhesion-reduction agent.
The study was carried on in three different centers in Germany: University Hospital for Gynecology
Pius-Hospital Oldenburg, Department for Obstetrics and Gynecology of Johanna-Etienne-Clinic, Neuss
and in the Clinic for Minimal Invasive Surgery, Berlin-Zehlendorf, Germany.
The study was single blind e subject and the investigators were blinded to treatment group
assignment until completion of uterine suturing and prior to removal of the endoscope. Randomization
was undertaken in blocks of 3 (2 intervention patients and 1 surgery only control), recruiting a min-
imum of 3 complete blocks at each centre to ensure no domination between centres. The objective of
study was to assess safety as primary end e point, as well as manageability and usability as secondary
end e points, of the ADBLOCK Adhesion Barrier System in laparoscopic surgery.
Safety evaluation
A vigorous follow-up of subjects was organized, focusing on its two critical characteristics:
completeness and duration. Completeness of follow-up was deﬁned by percentage of subjects entering
the study who returned to each and every planed follow-up appointments [26]. The clinical subjects
were observed and evaluated in a speciﬁc period of time, which represented the duration of follow-up
[26].
Safety of the ADBLOCK was estimated after analyzing and documentation of any adverse events
occurred, clinical and physical examination of patients as well as evaluation of laboratory measures.
For every reported adverse event, the investigator was required to determine if there was a rela-
tionship between the study treatment and the event. The relationship could be rated as “not related”,
“unlikely”, “possible”, “probable”, or “highly probable”.
In our series, the patients were followed e up at 7 and 14 days post-discharge. If a clinic visit was
not practical for the patient, a centralized hospital follow-up by telephone was accepted. After the 28-
day assessment, the subjects were investigated through telephone interviews at 12 weeks. For sec-
ondary end e point analysis, a prolonged and centralized follow-up period out to 24 months was
carried on. Patients were assessed at 6, 12 and 24 months. The assessments included: abdominal pain,
discomfort, distension, well-being evaluation, normal daily function, pregnancy, birth, miscarriage,
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procedure e related hospitalizations. Patients consenting to be included in the study were required to
take contraceptive measures for the ﬁrst 12 weeks post surgery. Pregnancy assessments at days 7, 14
and 28 days and 12 weeks post discharge were made in order to evaluate the coherence of subjects to
inclusion criteria. The pregnancy evaluation at 6, 12 and 24 months were only undertaken in women
seeking to become pregnant. This follow up allowed a comprehensive review of the safety of
ADBLOCK.
Results
Disposition of subjects
A total of 32 patients were enrolled in the ADBEE study in 3 sites in Germany, between 21.08.2012
and 30.11.2012. The study enrolment is summarized in Table 1.
Two patients (one patient from each group) were excluded, having a reported pneumoperitoneum
of more than 90 min.
Thirty patients were discharged in time and two patients (one in each treatment group) remained
longer than required. The follow up of the patients was undertaken by hospital visit at 7,14 and 28 days,
at 12 weeks, and 6, 12 and 24 months post-procedure. At 28 days, follow-up was performed in 32
patients.
The disposition of patients per time-point is provided in the ﬂowchart below (Fig. 1).
Clinical events and safety review
There were no safety concerns reported in our series.
Compliance of patients
The number of all protocol deviations per different category is summarized in Table 2. All of them
could be deﬁned as minor deviations due to missing data, assessments out of windows or lost follow-
up. The proportion of minor deviations was similar in both treatment groups. None of these deviations
were considered to have any signiﬁcant effect on the safety of patients or study outcome measures.
No patient withdrew informed consent and there were neither major protocol deviations nor major
deviation from Good Clinical Practice (GCP). Two patients with pneumoperitoneum > 90 min were
excluded.
Primary endpoints: safety endpoints
Adverse events up to 28 days following surgery
The numbers of subjects reporting adverse events in the ﬁrst 28 days following surgery are sum-
marized in Table 3. All AEs were considered not related or unlikely to be related to study device.
There was no signiﬁcant difference in proportion of events reported between both treatments at 28
days (p ¼ 0.440). Overall, the number of events reported was low and the severity of events was
generally mild, being unlikely or not related to treatment.
Type of adverse events up to 28 days post surgery
Table 4 summarizes the AEs reported in the study during the ﬁrst 28 days, by event. The most
common AE was a post-operative pain score of >5, with six reports in the ADBLOCK group and ﬁve inTable 1
The number of enrolled patients.
Number of patients/Randomization Randomized
ADBLOCK NO-ADBLOCK
Total of patients 21 11
Randomization 2 1
Fig. 1. Disposition of patients' follow up.
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related). There were no severe events in the ﬁrst 28 days following surgery.
Secondary endpoints
Manageability and usability
Overall, the investigators found the ADBLOCK system simple to use. There were no procedural SAEs
during the study and ADBLOCKwas administered in all 21 patients randomized to receive treatment. In
18 patients, one kit was used. In two patients, more than one kit was required, due to device failure
during preparation. Simplicity of setting up was generally rated as OK (36%) or simple (32%) or very
simple (20%).Table 2
Summary protocol deviations.
Missing data Follow-up performed outside
of windows
Lost follow-up
n ¼ number of patients
(percentage of patients)
n ¼ number of patients
(percentage of patients)
n ¼ number of patients
(percentage of patients)
ADBLOCK Surgery only ADBLOCK Surgery only ADBLOCK Surgery only
Enrolled subjects 21 11 21 11 21 11
Subjects PD was applied 15 (71%) 8 (72%) 14 (67%) 5 (45%) 6 (29%) 1 (9%)
Table 3
Summary of Treatment-Emergent Adverse Events by Number of Patients over the ﬁrst 28 days treatment.
Treatment group
ADBLOCK
(N ¼ 21)
NO-ADBLOCK
(N ¼ 11)
Events Patients n (%) Events Patients n (%)
Total number of TEAE*s 13 10 (50) 8 7 (70)
Relationship to device
Not related 10 8
Unlikely related 3 0
Mild 12 7
Moderate 1 1
Serious 1 0
*Treatment Emergent Adverse Event (TEAEs) are deﬁned as events starting or worsening after ﬁrst dose of study treatment.
Table 4
Adverse Event Overview at 28 days.
Body system ADBLOCK
(N ¼ 21)
NO-ADBLOCK
(N ¼ 11)
Total number of events
Mild Moderate Mild Moderate
Post Operative Pain  5 01e10 UR*
02e03 NR**
02e05 NR
02e10 NR
03e02 NR
03e05 NR
01e02 NR
02e01 NR
02e08 NR
03e01 NR
03e10 NR
11 (11)
Upper abdominal pain 02e09 NR 1 (1)
Dysmenorrhoe 01e04 UR 1 (1)
Dysmenorrhoe & pain 01e06 NR 1 (1)
Abdominal skin neuralgia 02e01 NR 1 (1)
CRP Elevation 01e10 UR*** 1 (1)
Nausea 02e03 NR
02e09 NR
2 (2)
Back Pain 02e07 NR 1 (1)
Allergic skin reaction (plaster) 03e04 NR 1 (1)
Vertigo 03e06 NR
03e09 NR
2 (1)
Total 12 1 8 1
*NR ¼ Not related; **UR ¼ Unlikely related; ***Event also reported as an SAE as this mild elevation in CRP resulted in prolon-
gation of hospitalization.
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simple (27%). Visualisation after spraying was estimated as being positive, with overall positive
satisfaction.
Device failure malfunction
Overall, 25 kits of ADBLOCKwere applied for 21 patients in the study, including the 2 kits used in the
patients excluded, due to the requirement of a pneumoperitoneum >90 minutes. There were 3 device
failures out of 25 (12% frequency). All cases occurred during preparationphase so no AE occurred due to
these failures.
Unanticipated device e related adverse events
There were no unanticipated device related adverse events seen in both treatment groups over the
immediate post-operative period or during the 24 months follow up period.
Table 5
Bowel function after surgery.
Assessment ADBLOCK NO-ADBLOCK
Number of
Patients
% Of Patients Number of
Patients
% Of Patients P Value
Bowel Sounds Quicker than expected 1 6.67 0 0
As expected 14 93.33 8 100
Later than expected 0 0 0 0
First Meal Quicker than expected 0 0 0 0
As expected 21 100 11 100
Later than expected 0 0 0 0
First ﬂatus Quicker than expected 3 20 0 0 0.2299
As expected 10 66.67 8 100
Later than expected 2 13.33 0 0
First bowel movement Quicker than expected 0 0 0 0
As expected 15 100 8 100
Later than expected 0 0 0 0
Did the patient
experience ileus
No 21 100 11 100
Yes 0 0 0 0
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Theatre recovery room. All patients were transferred to the ward within a reasonable period of time
following surgery and there was no difference in transfer time between both treatment groups. Table 5
summarizes data relating to postoperative bowel function. There were no signiﬁcant clinical relevant
differences regarding bowel function between both treatment groups. Most observations were rated as
expected and no patient experienced ileus.
Ward recovery. After transfer to the ward, all patients announced uncomplicated wounde and port site
e healing, with no signiﬁcant difference in pain score between groups. Using a pain rating scale from
0 to 10 (0 being no pain), the pain scores reported by patients were similar in both treatment groups.
The mean pain scores were 4.8 ± 1.8 and 4.1 ± 1.6 in the ADBLOCK and NO-ADBLOCK group respec-
tively. Patient's general pain score over six days is detailed in Table 6.
Table 7 summarizes patient's rating for shoulder pain, abdominal discomfort and abdominal
distension for Day 1. No ratings were of clinical concern. Similar ﬁndings were reported during the
patient recovery Days 2e7.
The scores for general well e being did not signiﬁcantly differ between treatment groups, with
mean ± SD scores (on a scale of 1 to 10) on Day 1, being 3.2 ± 2.6 and 3.0 ± 2.9 in ADBLOCK and NO-
ADBLOCK group, respectively. These scores of general well e being on days 1 to 7 are outlined in
Table 8.
No patient developed a fever of clinical concern.
Discharge. All patients, except two from ADBLOCK group, were discharged as expected. In one case,
prolonged hospitalization was recorded due to patient's choice. The other patient experienced anTable 6
Patient's general pain.
ADBLOCK NO-ADBLOCK P Value
Number of
Patients
Mean ± SD
Score
Number of Patients Mean ± SD
Score
Day 1 21 4.8 ± 1.79 11 4.1 ± 1.62 0.2338
Day 2 21 3.4 ± 2.12 11 2.9 ± 1.81 0.4488
Day 3 14 2.0 ± 1.36 7 2.1 ± 1.57 0.9830
Day 4 10 1.9 ± 0.77 4 1.8 ± 1.04 0.7254
Day 5 5 1.1 ± 1.15 4 1.9 ± 1.51 0.3935
Day 6 1 2 2 2.5 ± 0.71
Table 7
Patient's rating for shoulder pain, abdominal discomfort and abdominal distension.
Assessment ADBLOCK NO-ADBLOCK
Number of Patients Score ± SD Number of Patients Score ± SD P Value
DAY 1
Shoulder pain 21 3.12 ± 2.43 11 1.14 ± 1.64 0.022
Abdominal discomfort 21 4.2 ± 1.55 11 2.75 ± 2.21 0.038
Abdominal distension 21 3.18 ± 2.56 11 2.95 ± 2.91 0.819
DAY 2
Shoulder pain 21 2.4 ± 2.10 11 0.73 ± 1.56 0.0274
Abdominal discomfort 21 2.7 ± 2.41 11 2.34 ± 1.61 0.6607
Abdominal distension 21 2.11 ± 2.27 11 2.5 ± 2.59 0.6630
DAY 3
Shoulder pain 14 1.67 ± 1.89 7 0.71 ± 1.89 0.2877
Abdominal discomfort 14 2.4 ± 1.37 7 2.07 ± 1.45 0.6179
Abdominal distension 14 2.24 ± 1.46 7 2.13 ± 2.53 0.8960
DAY 4
Shoulder pain 10 0.15 ± 0.34 4 0.50 ± 1.00 0.5389
Abdominal discomfort 10 1.72 ± 1.01 4 2.25 ± 2.18 0.5333
Abdominal distension 10 1.89 ± 1.20 4 1.43 ± 0.67 0.4864
DAY 5*
Shoulder pain 5 0 4 0.25 ± 0.50 0.3910
Abdominal discomfort 5 1.54 ± 1.31 4 1.63 ± 1.80 0.9367
Abdominal distension 5 1.6 1.9 4 0.8 ± 0.91 0.4686
*Data beyond day 5 is not presented as limited data was available due to discharge.
Table 8
Patient general well e being.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Mean ± SD
Score
Number of Patients Mean ± SD
Score
Day 1 21 4.3 ± 1.81 11 3.9 ± 1.87 0.5861
Day 2 21 3.0 ± 1.88 11 2.6 ± 1.44 0.4635
Day 3 14 2.5 ± 1.14 7 2.2 ± 1.58 0.6641
Day 4 10 2.4 ± 0.95 4 2.4 ± 2.02 0.9240
Day 5 5 2.1 ± 2.01 4 1.6 ± 1.14 0.6851
Day 6 1 2 2 1.8 ± 0.35
C. Cezar et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 35 (2016) 97e112104adverse event, mild and asymptomatic elevation of CRP value, requiring clinical evaluation and labo-
ratory tests that resulted in prolongation of stay. Average time to discharge was 3.4 days in ADBLOCK
arm and 3.6 days in NON-ADBLOCK arm (p ¼ 0.709).
By discharge, all patients remained blind regarding whether or not they received ADBLOCK. They all
obtained clear instructions for follow-up period.
Post discharge follow-up day 7 to 28. Patients were followed up at 7, 14 and 28 days following surgery.
Thewound's healing was good in all patients from both treatment groups, on day 7. By day 14, in the
ADBLOCK group, 4 patients (19%) reported their wound as healed and the rest of subjects declared it to
be healing well. Similarly, in NO-ADBLOCK group, the wound was healed in a proportion of 18%, one
patient reported a moderate healing and the rest of the subjects announced a well healing wound. By
day 28,18 patients (90%) of the ADBLOCK reported their wound as healedwith only 2 (10%) announcing
healing well. In the NO-ADBLOCK group, 100% of patients reported their wound as healed. For this
follow up at 28 days, 1 report was missing.
Table 9
Patient post-discharge scores for abdominal symptoms and well e being at 7e28 days.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Mean ± SD
Score
Number of
Patients
Mean ± SD
Score
Day 7
Pain (General) 21 1.5 ± 1.7 11 1.1 ± 1.6 0.5603
Pain (abdominal) 21 2.1 ± 2.0 11 1.2 ± 1.7 0.2212
Abdominal tenderness 21 1.4 ± 1.6 11 0.8 ± 1.5 0.2979
Abdominal discomfort 21 1.5 ± 2.0 11 0.5 ± 0.5 0.0289
Abdominal distension 21 1.0 ± 1.5 11 0.7 ± 1.5 0.6072
General Wellbeing 21 2.0 ± 1.7 11 1.1 ± 1.1 0.1123
Normal Daily function 21 3.1 ± 2.1 11 1.9 ± 1.6 0.1245
Day 14
Pain (General) 21 1.1 ± 1.2 11 0.9 ± 2.1 0.7683
Pain (abdominal) 21 1.9 ± 1.7 11 1.0 ± 2.1 0.1871
Abdominal tenderness 21 1.1 ± 1.4 11 1.1 ± 3.0 0.9576
Abdominal discomfort 21 1.0 ± 1.3 11 0.7 ± 1.6 0.5282
Abdominal distension 21 0.9 ± 1.5 11 0.4 ± 0.8 0.1830
General Wellbeing 21 1.3 ± 0.9 11 0.8 ± 1.5 0.2936
Normal Daily function 21 1.9 ± 1.4 11 1.4 ± 2.0 0.3952
Day 28
Pain (General) 20 0.5 ± 1.3 11 0.3 ± 0.7 0.4472
Pain (abdominal) 20 0.7 ± 1.3 11 0.7 ± 1.4 0.8662
Abdominal tenderness 20 0.4 ± 0.8 11 0.2 ± 0.6 0.4394
Abdominal discomfort 20 0.8 ± 1.2 11 0.2 ± 0.6 0.1112
Abdominal distension 20 0.6 ± 0.9 11 0.4 ± 0.8 0.5756
General Wellbeing 20 0.7 ± 1.2 11 0.3 ± 0.7 0.1876
Normal Daily function 20 0.8 ± 1.1 11 0.3 ± 0.6 0.1932
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daily function reported by patients post e discharge, over day 7 to 28.
Therewere no statistical signiﬁcant differences between both treatment groups, with one exception
of abdominal discomfort at day 7 recorded as being higher in ADBLOCK than in the NO-ADBLOCK group
(p ¼ 0.0289). However all other measures at day 7 were similar. This did not impact on normal daily
function.
The use of painkillers is detailed in Table 10. A similar proportion of patients were using painkillers
in both treatment groups across the 28 days following treatment.
Post-discharge follow-up 12 weeks, 6, 12 and 24 months. The patients were followed up at 12 weeks, 6, 12
and 24 months following surgery. By 12 weeks, all patients reported their wound as healing well or
healed and at 6 months all wounds were reported as healed. The use of painkillers in this period is
schematized in Table 11. There were no differences between both treatment groups regarding the use
of painkillers over 24 months follow up period.Table 10
Patient reports for use of painkillers 7 to 28 days.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Number of Patients
Day 7 Pain-Killers
Yes 16 (76%) 8 (73%) 1
No 5 (24%) 3 (27%)
Day 14 Pain-Killers
Yes 16 (76%) 9 (82%) 1
No 5 (24%) 2 (18%)
Day 28 Pain-Killers
Yes 19 (95%) 10 (91%) 1
No 1 (5%) 1 (9%)
Table 11
Patient reports of use of painkillers at 12 weeks to 24 months.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Number of Patients
12 weeks Pain-Killers
Yes 2 (10%) 1 (9%) 1
No 19 (90%) 10 (91%)
6 Months Pain-Killers
Yes 2 (10%) 1 (9%) 1
No 18 (90%) 10 (91%)
12 Months Pain-Killers
Yes 1 (5%) 1 (9%) 1
No 18 (95%) 10 (9%)
24 Months Pain-Killers
Yes 0 (0%) 0 (0%) 1
No 16 (100%) 10 (100%)
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from the patients over 24 months of follow-up are summarized in Table 12. Generally, over a period of
24 months, there are no statistical relevant differences regarding clinical state between both groups.
There is though at 12 months a statistical signiﬁcant difference between the two treatment groups in
respect to general well e being (p ¼ 0.0210) and normal daily function (p ¼ 0.0299) scores. However
these are unlikely to be of clinical relevance.
Pregnancy and birth. Table 13 summarizes the rates of pregnancy and birth reported in both groups. No
patient became pregnant in the 28 days follow up period. There were no differences between both
groups in terms of pregnancies during the 24 months follow up period.
In ADBLOCK arm, 2 cases out of 5 decided to perform abortion, 2 patients had a healthy baby (one
case vaginal birth and one caesarean section). One patient was lost from follow up. In surgery only arm,
3 patients delivered a healthy baby.
Summary of adverse events up to 24 months following surgery. Table 14 summarizes the number of sub-
jects reporting adverse events and also AEs deﬁned in accordance to device's relationship (ADBLOCK/
NO-ADBLOCK) as judged by the investigator.
There were 25 (57%) adverse events reported in ADBLOCK treatment group and 12 (73%) events in
NO-ADBLOCK group. All adverse events in both treatment arms were not anticipated, with all events in
the ADBLOCK group being resolved.
Most of the events were mild. Severe events reported in both groups were related to surgical
procedures, none of them being related to device. All events were estimated as not-related or unlikely
to be related to the study device.
Most adverse events were managed with either observation (48 and 42% in the ADBLOCK and NO-
ADBLOCK treatment group respectively), or prescription (12 and 17% in the ADBLOCK and NO-
ADBLOCK treatment group respectively). A small number also required “other treatment”, 24% and
25% in ADBLOCK and NO- ADBLOCK treatment group respectively. No treatments were considered to
have any impact on the study outcomemeasures or patient safety. The small number of adverse events
that required hospitalisation or prolongation of hospitalisation were reported as SAEs, but none of
them being related to study device.
Tables 15 and 16 include AEs reported in the study by event and number of patients for FAS for the
ﬁrst 28 days and 24 months respectively. Overall the incidence of AEs was low, with little or no
relationship to study device. There were no differences between the two treatment groups regarding
safety of subjects.
Deaths, other serious adverse events, and other signiﬁcant adverse events. No deaths or unexpected AEs
were reported during the study. After 24 months there were more serious adverse events (SAEs) re-
ported in ADBLOCK group, however the nature of the SAEs being not related to the trial. Except one, all
Table 12
Post discharge scores for abdominal symptoms and well e being at 12 weeks and 24 months.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Mean ± SD
Score
Number of Patients Mean ± SD
Score
Week 12
Pain (General) 21 0.7 ± 1.42 11 0.3 ± 0.9 0.4088
Pain (abdominal) 21 0.5 ± 1.25 11 0.5 ± 1.51 0.8906
Abdominal tenderness 21 0.3 ± 0.97 11 0 ± 0 0.1295
Abdominal discomfort 21 0.5 ± 1.21 11 0.3 ± 0.9 0.7064
Abdominal distension 21 0.3 ± 0.91 11 0.1 ± 0.3 0.2781
General Wellbeing 21 0.8 ± 1.58 11 0.2 ± 0.61 0.1811
Normal Daily function 21 0.7 ± 1.43 11 0.5 ± 1.04 0.6664
6 Months
Pain (General) 20 0.3 ± 0.8 11 0.2 ± 0.61 0.7953
Pain (abdominal) 20 0.4 ± 0.99 11 0.2 ± 0.6 0.5140
Abdominal tenderness 20 0.2 ± 0.7 11 0.1 ± 0.15 0.3507
Abdominal discomfort 20 0.2 ± 0.67 11 0.2 ± 0.6 0.8969
Abdominal distension 20 0.5 ± 1.28 11 0.1 ± 0.15 0.1318
General Wellbeing 20 0.5 ± 0.89 11 0.2 ± 0.61 0.4651
Normal Daily function 20 0.3 ± 0.8 11 0.2 ± 0.6 0.6732
12 Months
Pain (General) 19 0.1 ± 0.32 11 0 ± 0 0.1628
Pain (abdominal) 19 0.3 ± 0.81 11 0.2 ± 0.6 0.7738
Abdominal tenderness 19 0 ± 0 11 0 ± 0
Abdominal discomfort 19 0.4 ± 0.96 11 0.1 ± 0.3 0.1794
Abdominal distension 19 0.5 ± 1.07 11 0 ± 0 0.0704
General Wellbeing 19 0.8 ± 1.27 11 0.1 ± 0.'5 0.0210
Normal Daily function 19 0.6 ± 1.07 11 0 ± 0 0.0299
24 Months
Pain (General) 16 0.4 ± 1.3 10 0 ± 0 0.2628
Pain (abdominal) 16 0.4 ± 1.02 10 0 ± 0 0.1639
Abdominal tenderness 16 0 ± 0 10 0 ± 0
Abdominal discomfort 16 0.2 ± 0.75 10 0 ± 0 0.3332
Abdominal distension 16 0.6 ± 1.75 10 0.1 ± 0.32 0.3176
General Wellbeing 16 0.7 ± 1.85 10 0.1 ± 0.32 0.2323
Normal Daily function 16 0.3 ± 0.77 10 0 ± 0 0.2162
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the device. The only SAE occurring in the 28 days following surgery was a raised CRP. This was mild in
severity but resulted in prolongation of hospitalisation, a clinical monitoring of the patient being
necessary. In this way, the case fell into the category of SAE althoughmild and not related to the device.
This was the only SAE occurring during the ﬁrst 28 days following treatment.
Laboratory tests. Changes in laboratory values, during follow up period were generally of no clinical
relevance and no adverse event was reported. Most laboratory measures remained within normal
ranges, in both ADBLOCK and NO-ADBLOCK group. Measures outside the reference ranges for the
laboratory were considered though to be normal (i.e. not of clinical relevance or signiﬁcant for the
study). There was one laboratory value (elevated CRP in one patient) that was reported as SAE, as this
resulted in prolongation of hospitalisation.
Discussion
Current state of research regarding existing anti-adhesion agents highlights that a safe and effective
anti-adhesion gel to be used both in open and also in laparoscopic surgery is of a great value, partic-
ularly in surgical procedures with a recognised high risk of adhesions including myomectomy
Table 13
Pregnancy reports at 12 weeks to 24 months.
ADBLOCK NO-ADBLOCK P Value
Number of Patients Number of Patients
12 weeks
Pregnant
Yes 0 0% 0 0%
No 21 100% 11 100%
6 Months
Pregnant
Yes 2 10% 1 9% 1
No 18 90% 10 91%
12 Months
Pregnant
Yes 4 21% 2 18%
No 15 79% 8 73% 0.5961
24 Months
Pregnant
Yes 0 0% 1 10%
No 16 100% 9 90% 0.3846
Table 14
Summary of treatment-emergent Adverse Events by number of patients and number of events over the 24-months treatment.
Treatment group P Value
ADBLOCK
(N ¼ 21)
NO- ADBLOCK
(N ¼ 11)
N N
Adverse Event? No 9 (43%) 3 (27%) 0.464
Yes 12 (57%) 8 (73%)
Number of events 25 12
Severity Mild 18 (72%) 10 (83%) 0.832
Moderate 2 (8%) 1 (8%)
Severe 5 (20%) 1 (8%)
Serious No 19 (76%) 11 (92%) 0.389
Yes 6 (24%) 1 (8%)
Relationship to study product Not related 18 (72%) 12 (100%) 0.072
Unlikely 7 (28%) 0 (0%)
Treatment none 12 (48%) 5 (42%) 1
Required prescription 3 (12%) 2 (17%)
hospitalization required/prolonged 4 (16%) 2 (17%)
other treatment required 6 (24%) 3 (25%)
Outcome resolved 22 (88%) 10 (83%)
resolving 3 (12%) 1 (8%)
not resolved 0 (0%) 1 (8%)
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have the best chance to improve their fertility outcomes [27]. However, even adopting the laparoscopic
approach and even if undertaken in patients who didn't require previous adhesiolysis for pre-existent
adhesions, the procedure itself is burdened by a signiﬁcant rate of de novo adhesions formation with
negative impact on successful fertility outcomes, as well as increasing the risk of other adhesion-
related complications or impacting on future abdominopelvic surgery [24,28e30]. Patients undergo-
ing removal of posterior myoma are at most risk of adhesions formation, with high rates of developing
to the posterior uterus, rectosigmoid and adnexa [25,31,32].
Given the high risk of adhesions and the negative impact on clinical outcomes, many surgeons
undertake a second look laparoscopy to lyse any adhesions at an early stage of formation in order to
Table 15
Summary of treatment-emergent Adverse Events by number of patients over the ﬁrst 28 days treatment (FAS Analysis Set).
Treatment group
ADBLOCK
(N ¼ 20)
NO-ADBLOCK
(N ¼ 11)
Events Patients n (%) Events Patients n (%)
Total number of TEAE*s 13 10 (48) 9 8 (73)
Relationship to device
Not related 11 9
Unlikely related 2 0
Mild 11 8
Moderate 1 1
Serious 1 0
*Treatment Emergent Adverse Event, treatment emergent adverse events (TEAEs) are deﬁned as events starting or worsening
after ﬁrst dose of study treatment.
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allows also to examine the integrity of uterine scar [33].
Many anti-adhesion agents have been assessed in patients undergoing myomectomy and recent
researches highlight that during procedures such as myomectomy, a site-speciﬁc barrier gel agent is a
particularly useful strategy to reduce adhesions [34e37].
The ADBLOCK System has been investigated as a site e speciﬁc sprayable adhesion barrier gel for
the use not only in laparotomy but also in laparoscopy. Preclinical researches undertaken in accordance
with ISOs and FDA guidance provided evidence of both safety and efﬁcacy of ADBLOCK in reduction of
adhesions in standard animal models [1]. Forwards, we conducted a clinical ﬁrste ine human study to
evaluate safety, manageability and usability of ADBLOCK Adhesion Barrier System [1]. An important
step in safety evaluation of ADBLOCK System was the conduction of a rigorous follow up care of the
subjects, in order tomonitor the postoperative recovery as well as to diagnose andmanage any possible
adverse events.
Patient groups were well matched at baseline and surgical procedures performed in accordance
with the surgical technique outlined in the Clinical Investigational Plan, with experienced surgeons
undertaking the procedures. The surgical method, as well as the density of adhesions were properly
selected for the ADBLOCK and surgery only groups. Therefore, there was little difference at baseline.
In terms of safety, as primary endpoint, there was no difference between those patients who
received ADBLOCK and those who had surgery alone, the adverse events at 28 days being similar in
both groups, mild in nature and also not related, or unlikely to be related to the treatment.
No serious adverse events were related to treatment. Only one laboratory measure (ADBLOCK
group) was reported as AE (SAE due to prolonged hospitalisation), being of mild severity and resolved
within four days.
The most frequently reported AE was a post-operative pain score of 5, which could be anticipated
in patients undergoing this type of surgery, the proportions of reports in both treatment groups being
however equal.
The secondary endpoints studied were manageability and usability of device. The overall usability
was good, all of investigators rating the spraying as being more than OK. According to most of the
ratings, the device was simple or very simple to use. Device failure's rate was low and occurred prior to
use, so that it didn't interfere with the operative procedure. All powders dissolved in all cases. Overall,
the satisfaction regarding the device was positive.
As anticipated, post-operative recuperation was good, with recovery and healing being similar in
both groups, ADBLOCK and surgery alone. There were no differences reported regarding the ward
recovery in both groups, the ratings from surgeon being good or better than expected. The pain scores
were also similar in both groups. These scores were relatively low in the 28 days following surgery and
the use of painkillers was similar between both treatments groups. The impact on daily function was
low, the scores for normal daily function as well as for general welle beingwere similar in both arms of
study, with no signiﬁcant difference between them.
Table 16
Summary of treatment-emergent Adverse Events by number of patients over the 24 months treatment (FAS Analysis Set).
Treatment group
ADBLOCK
(N ¼ 19)
NO-ADBLOCK
(N ¼ 10)
Events Patients n (%) Events Patients n (%)
Total number of TEAE*s 25 12 (57) 12 8 (73)
Relationship to device
Not related 18 12
Unlikely related 7 0
Mild 18 10
Moderate 2 1
Severe 5 1
Serious 6 1
*Treatment Emergent Adverse Event, Treatment emergent adverse events (TEAEs) are deﬁned as events starting or worsening
after ﬁrst dose of study treatment.
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differences between treatment groups.
There were no differences registered concerning pregnancies' and births' rates in both groups,
almost 20% of patients being pregnant at 12 months after surgery in both arms.
The incidence of adverse events over a period of 24 months follow up was low, these events being
unremarkable and similar between the two groups. The cases recorded as SAEs fell into this category of
deﬁnition, but there were planned surgical procedures, rather than medical concerns.
Except one case of mild elevated CRP, there were no notable changes in laboratory variables.
Conclusion
This clinical ﬁrst e in e human study, sustained by the rigorous follow-up of the subjects has
demonstrated that ADBLOCK is a safe product, presenting no additional safety risk or burden to the
patients, comparing to surgery alone. The device was easy to use, with a low rate of device's failure
which, however, didn't have any impact on the surgical procedures.
Conﬂict of interests
None declared.Research Agenda
Follow-up up to 2 years in the study and/or planned studies will address efficacy of ADBLOCK in
prevention of adhesions.
Practical points
 Preclinical studies, biochemical safety
 Clinical studies with three ethical principles:
 Safety of the human subjects
 Obligation to do no harm
 Equitable proportion of advantages and disadvantages.
 Follow e up of the subjects
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